Posted in anti-rabbit alexa fluor 488, Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, Elisa Kits, Enzymes, epo elisa kit, Equipments, Exosomes, Gels, human il-2 elisa, human il2 elisa, il15ra elisa, il1rl2 antibody, Isotypes, lmbrd1 antibody, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides, pgf elisa, platelet lysate, Reagents, Recombinant Proteins, Ria Kits, RNA, s100a12 elisa, Test Kits, Vector & Virus, Western Blot

ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay

gentaur.com

Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature.

The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer).
Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer.
  • The concentrations of the 10 proteins (A1AT; apolipoprotein E-APOE; angiogenin-ANG; carbonic anhydrase 9-CA9; interleukin 8-IL-8; matrix metalloproteinase 9-MMP-9; matrix metalloproteinase 10-MMP10; plasminogen activator inhibitor 1-PAI-1; syndecan-SDC1; and vascular endothelial growth factor-VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications.
  • The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA).
  • The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.
gentaur.com
gentaur.com

PSMB8 Antibody
BF0434 200ul
EUR 540

PSMB8 Antibody
1-CSB-PA775839
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100

PSMB8 Antibody
1-CSB-PA116429
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100

PSMB8 Antibody
1-CSB-PA018886GA01HU
  • EUR 716.40
  • EUR 399.60
  • 150ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF

PSMB8 Antibody
1-CSB-PA018886LA01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

PSMB8 Conjugated Antibody
C43134 100ul
EUR 476.4

Anti-PSMB8 antibody
STJ11100809 100 µl
EUR 495.6
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.

Anti-PSMB8 antibody
STJ29479 100 µl
EUR 332.4
Description: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.

PSMB8 Polyclonal Antibody
A73468-050 50 ul
EUR 377.3

PSMB8 Polyclonal Antibody
A73468-100 100 ul
EUR 577.5

PSMB8 Polyclonal Antibody
A73468
  • EUR 377.30
  • EUR 577.50
  • 50 ul
  • 100 ul

Psmb8/ Rat Psmb8 ELISA Kit
ELI-15652r 96 Tests
EUR 1063.2

PSMB8 siRNA
20-abx904317
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

PSMB8 siRNA
20-abx930156
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

PSMB8 siRNA
20-abx930157
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

pOTB7-PSMB8
PVT18497 2 ug
EUR 277.2

PSMB8 Antibody, HRP conjugated
1-CSB-PA018886LB01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

PSMB8 Antibody, FITC conjugated
1-CSB-PA018886LC01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

PSMB8 Antibody, Biotin conjugated
1-CSB-PA018886LD01HU
  • EUR 380.40
  • EUR 402.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

PSMB8 Rabbit pAb
A7340-100ul 100 ul
EUR 369.6

PSMB8 Rabbit pAb
A7340-200ul 200 ul
EUR 550.8

PSMB8 Rabbit pAb
A7340-20ul 20 ul
EUR 219.6

PSMB8 Rabbit pAb
A7340-50ul 50 ul
EUR 267.6

PSMB8 Blocking Peptide
BF0434-BP 1mg
EUR 234

anti-PSMB8 (1A5)
LF-MA30618 100 ul
EUR 632.4
Description: Mouse Monoclonal to PSMB8

Monoclonal PSMB8 Antibody, Clone: 1A5
AMM02864G 0.1ml
EUR 633.6
Description: A Monoclonal antibody against Human PSMB8. The antibodies are raised in Mouse and are from clone 1A5. This antibody is applicable in WB and IHC, ICC, E

Anti-PSMB8 / LMP7 Monoclonal Antibody
M02188-2 100ug
EUR 476.4
Description: Rabbit Monoclonal PSMB8 / LMP7 Antibody. Validated in IP, IF, WB and tested in Human, Mouse, Rat.

PSMB8 protein (His tag)
80R-2608 100 ug
EUR 386.4
Description: Purified recombinant PSMB8 protein

Human PSMB8 shRNA Plasmid
20-abx953843
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Rat PSMB8 shRNA Plasmid
20-abx984734
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Mouse PSMB8 shRNA Plasmid
20-abx971337
  • EUR 961.20
  • EUR 1345.20
  • 150 µg
  • 300 µg

Canine PSMB8 ELISA KIT
ELI-15651d 96 Tests
EUR 1113.6

PSMB8 Recombinant Protein (Rat)
RP222629 100 ug Ask for price

PSMB8 Recombinant Protein (Human)
RP085356 100 ug Ask for price

PSMB8 Recombinant Protein (Mouse)
RP165287 100 ug Ask for price

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
20-abx141396
  • EUR 444.00
  • EUR 727.20
  • EUR 360.00
  • 100 ul
  • 200 ul
  • 50 ul

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
20-abx006453
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
20-abx114776
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
abx011689-100ul 100 ul
EUR 493.2

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
abx028154-400ul 400 ul
EUR 627.6

Proteasome Subunit Beta Type-8 (PSMB8) Antibody
abx028154-80l 80 µl
EUR 343.2

Proteasome subunit beta type-8 (PSMB8) Antibody
20-abx211178
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Proteasome subunit beta type-8 (PSMB8) Antibody
20-abx211851
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Monoclonal PSMB8 Antibody (monoclonal) (M01), Clone: 1B3
AMM03954G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human PSMB8 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1B3. This antibody is applicable in WB, IHC and IF, IP, E

[KO Validated] PSMB8 Rabbit pAb
A19933-100ul 100 ul
EUR 492

[KO Validated] PSMB8 Rabbit pAb
A19933-200ul 200 ul
EUR 685.2

[KO Validated] PSMB8 Rabbit pAb
A19933-20ul 20 ul
EUR 265.2

[KO Validated] PSMB8 Rabbit pAb
A19933-50ul 50 ul
EUR 344.4

PSMB8 ELISA Kit (Human) (OKEH07770)
OKEH07770 96 Wells
EUR 1310.4
Description: Description of target: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.06ng/mL

Psmb8 ORF Vector (Mouse) (pORF)
ORF055097 1.0 ug DNA
EUR 607.2

Psmb8 ORF Vector (Rat) (pORF)
ORF074211 1.0 ug DNA
EUR 607.2

PSMB8 ELISA Kit (Dog) (OKEH03975)
OKEH03975 96 Wells
EUR 1012.8
Description: Description of target: ;Species reactivity: Dog;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.064 ng/mL

PSMB8 ELISA Kit (Human) (OKCD02695)
OKCD02695 96 Wells
EUR 950.4
Description: Description of target: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.117 ng/mL

PSMB8 ORF Vector (Human) (pORF)
ORF028453 1.0 ug DNA
EUR 486

Psmb8 sgRNA CRISPR Lentivector set (Rat)
K6921501 3 x 1.0 ug
EUR 406.8

PSMB8 sgRNA CRISPR Lentivector set (Human)
K1740301 3 x 1.0 ug
EUR 406.8

Psmb8 sgRNA CRISPR Lentivector set (Mouse)
K4425601 3 x 1.0 ug
EUR 406.8

Human Proteasome subunit beta type-8 (PSMB8)
1-CSB-EP018886HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Proteasome subunit beta type-8(PSMB8) expressed in E.coli

Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 1)
K6921502 1.0 ug DNA
EUR 184.8

Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 2)
K6921503 1.0 ug DNA
EUR 184.8

Psmb8 sgRNA CRISPR Lentivector (Rat) (Target 3)
K6921504 1.0 ug DNA
EUR 184.8

PSMB8 sgRNA CRISPR Lentivector (Human) (Target 1)
K1740302 1.0 ug DNA
EUR 184.8

PSMB8 sgRNA CRISPR Lentivector (Human) (Target 2)
K1740303 1.0 ug DNA
EUR 184.8

PSMB8 sgRNA CRISPR Lentivector (Human) (Target 3)
K1740304 1.0 ug DNA
EUR 184.8

Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 1)
K4425602 1.0 ug DNA
EUR 184.8

Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 2)
K4425603 1.0 ug DNA
EUR 184.8

Psmb8 sgRNA CRISPR Lentivector (Mouse) (Target 3)
K4425604 1.0 ug DNA
EUR 184.8

PSMB8 Protein Vector (Human) (pPB-C-His)
PV113810 500 ng
EUR 662.4

PSMB8 Protein Vector (Human) (pPB-N-His)
PV113811 500 ng
EUR 662.4

PSMB8 Protein Vector (Human) (pPM-C-HA)
PV113812 500 ng
EUR 662.4

PSMB8 Protein Vector (Human) (pPM-C-His)
PV113813 500 ng
EUR 662.4

PSMB8 Protein Vector (Mouse) (pPB-C-His)
PV220386 500 ng
EUR 723.6

PSMB8 Protein Vector (Mouse) (pPB-N-His)
PV220387 500 ng
EUR 723.6

PSMB8 Protein Vector (Mouse) (pPM-C-HA)
PV220388 500 ng
EUR 723.6

PSMB8 Protein Vector (Mouse) (pPM-C-His)
PV220389 500 ng
EUR 723.6

PSMB8 Protein Vector (Rat) (pPB-C-His)
PV296842 500 ng
EUR 723.6

PSMB8 Protein Vector (Rat) (pPB-N-His)
PV296843 500 ng
EUR 723.6

PSMB8 Protein Vector (Rat) (pPM-C-HA)
PV296844 500 ng
EUR 723.6

PSMB8 Protein Vector (Rat) (pPM-C-His)
PV296845 500 ng
EUR 723.6

Comparison of Rapid Anti-HCV Multi-sure Kit with Gold Standard ELISA.

To compare the diagnostic yield of Multi-sure rapid HCV (hepatitis C virus) kit with ELISA.Comparative study.Pakistan Health Research Council, specialised research center for gastroenterology and hepatology, from August 2016 to January 2017.A modified rapid anti-HCV kit was compared with ELISA. This rapid kit is multi-parameter qualitative immune chromatographic kit for the in-vitro detection of antibodies to HCV in human blood.

  • Patients who came to PHRC, were tested using anti-HCV ELISA, and their test was run simultaneously on multi-sure HCV rapid kit were included in the study. Each positive and negative sample was included in this study. SPSS software was adapted for data analysis.A total of 420 samples were collected.
  • Among them, 255 (61%) were of male and 165 (39%) were of female patients. Mean age was 35 ± 14.33 years. All the samples run for anti-HCV on ELISA were also run on multi-sure rapid kit. It is evident that 22.4% were reactive on ELISA and 23.6% were reactive on rapid kit, while 75.5% were non-reactive on ELISA and 68.1% were non-reactive on rapid kit.
  • Borderline positive results were seen in 2.1% on ELISA and 5.0% on rapid kit. Sensitivity of rapid kit was 87.2%, specificity 89.3% with 82.8% positive predictive value and 98.9% negative predictive value.Multi-sure kit showed significantly, less non-reactive and more borderline results as compared to ELISA.
  • Comparison of multi-sure rapid kit with ELISA showed that core antibody can be used as an alternate marker for ELISA. Other non-structural proteins including NS3, NS4 and NS5 were found to be less significant. So, it is concluded that this rapid kit may not be recommended as an alternative of ELISA, except for places where ELISA is not available.

Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.

There are many studies presenting data of biologics and several ELISA kits commercially available for monitoring infliximab serum trough levels (s-IFXt) and anti-drug antibodies (ADAb). We propose to compare technical characteristics and results of three different assays on a cohort of 35 patients under infliximab (IFX) and suffering from inflammatory bowel disease (IBD).s-IFXt and ADAb were systematically measured with three ELISA kits: Lisa-Tracker® Duo infliximab (Theradiag®), Ridascreen® IFX Monitoring (R-Biopharm AG®) and Promonitor® IFX (Progenika Biopharma SA®).

The main technical features that differed between kits for measuring s-IFXt were: (i) TNF coating, (ii) immune complexes revelation strategy and/or (iii) interference with other anti-TNFα agents. For kits measuring ADAb, they were revelation steps and unit of results.

There was an excellent mathematical correlation of s-IFXt between assays however Bland-Altman analysis denoted (i) s-IFXt were on average 48 to 69% higher in Ridascreen® than in the other two assays, and (ii) elevated s-IFXt were higher with Promonitor® compared to Lisa-Tracker®.

As a consequence, there were some substantial discrepancies between assays for classification of s-IFXt into concentration ranges. Despite unstandardized units, pairwise qualitative comparison showed a perfect agreement between the three pairs of ADAb assays.

Our data show that the evaluated assays are not quantitatively interchangeable due to substantial variations in some results that could lead, for some patients, to divergent therapeutic decisions. We remind to be cautious when comparing study results issued from different kits and recommend using the same assay for the longitudinal follow-up of IBD patients

Brent